Observational studyESC heart failure2026
Clinical and echocardiographic changes after intermittent levosimendan infusion in patients with advanced heart failure.
Observational study in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo evaluate the short-term clinical, structural, and functional cardiac changes following intermittent levosimendan infusion and their prognostic implications in patients with advanced heart failure (AdHF).
methodsIn this prospective, multicentre, observational study, patients with AdHF treated with intermittent levosimendan infusion (12.5 mg at a rate of 0.1 μg/kg/min, without a bolus) were enrolled. Clinical, laboratory, and comprehensive echocardiographic assessments were performed at baseline, 48 h, and 30 days post-infusion. The primary endpoint was to evaluate the extent of clinical and cardiac structure and function changes during the first 30 days after levosimendan infusion. Secondary outcome of interest was the association of cardiac changes and a composite endpoint of decompensated HF, urgent HF rehospitalization, cardiogenic shock, cardiac arrest, and cardiovascular death at 6 months.
resultsA total of 37 patients with AdHF were included (mean age 71.1 ± 9.0 years; 59.5% male). A non-significant trend reduction in mean arterial pressure values was observed over time (81.3 ± 9.5 mmHg vs 80.9 ± 7.7 mmHg after 48 h vs 79.1 ± 6.9 mmHg at 30 days, P-value for trend = .079). NT-proBNP levels significantly decreased at 48 h and rose again by 30 days [from 1802 (1127-4436) ng/l to 1060 (830-3864) ng/l at 48 h and 1661 (1015-4245) ng/l at 30 days, P-value for trend = .006]. The main left ventricular (LV) and right ventricular (RV) structure and function parameters improved at 48 h but returned to baseline or a slight improvement by 30 days (LV ejection fraction: 30.9 ± 11.3% vs 32.2 ± 11.2%, vs 30.9 ± 11.3%, P-value for trend = .001; LV global longitudinal strain: -8.0 ± 3.5% vs -9.2 ± 3.5% vs -8.0 ± 3.3%, P-value for trend < .001; tricuspid annular plane systolic excursion: 16.9 ± 3.1 mm vs 17.7 ± 3.4 vs 17.0 ± 3.5, P-value for trend .007; systolic pulmonary artery pressure: 48.7 ± 15.8 mmHg vs 41.6 ± 12.7 mmHg vs 46.1 ± 15.0, P-value for trend <.001). Overall, 17 (45.9%) patients experienced CV events. After accounting for confounders, ΔLV global longitudinal strain (GLS) after 48 h (adjusted odds ratio (OR) 0.26, 95% confidence interval (CI) 0.10-0.67, P = .006) and ΔRV free wall longitudinal strain (FWLS) (adjusted OR 0.75, 95% CI 0.57-0.99, P = .041) were significantly associated with a lower risk of events.
conclusionsIn patients with AdHF, intermittent levosimendan infusion resulted in early improvements in NT-proBNP levels and biventricular function, which tended to wane by 30 days. Early enhancements in LVGLS and RVFWLS were independently associated with better clinical outcomes, suggesting their potential role as markers to guide patient selection and therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.